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Summary
To evaluate the probabilities of a disease state, ideally all subjects in a study should be diagnosed
by a definitive diagnostic or gold standard test. However, since definitive diagnostic tests are often
invasive and expensive, it is generally unethical to apply them to subjects whose screening tests
are negative. In this article, we consider latent class models for screening studies with two
imperfect binary diagnostic tests and a definitive categorical disease status measured only for
those with at least one positive screening test. Specifically, we discuss a conditional independent
and three homogeneous conditional dependent latent class models and assess the impact of
misspecification of the dependence structure on the estimation of disease category probabilities
using frequentist and Bayesian approaches. Interestingly, the three homogeneous dependent
models can provide identical goodness-of-fit but substantively different estimates for a given
study. However, the parametric form of the assumed dependence structure itself is not “testable”
from the data, and thus the dependence structure modeling considered here can only be viewed as
a sensitivity analysis concerning a more complicated non-identifiable model potentially involving
heterogeneous dependence structure. Furthermore, we discuss Bayesian model averaging together
with its limitations as an alternative way to partially address this particularly challenging problem.
The methods are applied to two cancer screening studies, and simulations are conducted to
evaluate the performance of these methods. In summary, further research is needed to reduce the
impact of model misspecification on the estimation of disease prevalence in such settings.
Keywords
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1. Introduction
Screening for a specific disease or condition is a fundamental component of human disease
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likely or unlikely to have the disease or condition of interest. People who appear likely to
have the disease or condition are examined further for a diagnosis, and those people who are
diagnosed with the disease are treated. Therefore, screening can reduce the morbidity and
mortality of the disease among people screened and can enable early treatment for diagnosed
cases. Screening programs for cancer and heart diseases are well established in many
countries. In many screening programs, a population with known size n is screened by two
imperfect binary diagnostic tests. If the results of both diagnostic tests are negative, no
further screening is undertaken. If either of the two diagnostic tests is positive, then a full
evaluation of the disease using a gold standard classification is undertaken [1].
For estimating diagnostic accuracy without a gold standard, it is well known that if the
conditional independence assumption is incorrectly assumed, parameter estimates may be
biased [2–4]. When the disease status D is a binary random variable, Albert and Dodd [5]
showed that the estimation of diagnostic accuracy and prevalence is sensitive to the choice
of dependence structure for studies with multiple diagnostic tests. The dependence structure
was specified using a Gaussian random effects model [6,7] and a finite mixture model [8].
They showed that it is difficult to distinguish between different dependence structures in the
absence of a gold standard test in most practical situations (i.e., unless there are more than
10 tests). Albert [9] proposed methods for estimating diagnostic accuracy of multiple binary
tests with an imperfect reference standard when information about the diagnostic accuracy
of the imperfect test is available from external data sources. Furthermore, using the same
dependence structure, Albert and Dodd [10] examined the effect of model misspecification
on the estimation of test accuracy and prevalence when a binary gold standard is partially
verified. They showed that for extreme biased sampling the estimation is sensitive to the
choice of dependence structure. Other latent class models with a focus on diagnostic
accuracy have also been considered in a single study [11,12] as well as in a meta-analysis
[13]. In addition, Black and Craig [14] discussed the estimation of disease prevalence in a
scenario involving two imperfect tests in the absence of a gold standard and proposed
Bayesian model averaging for inference over the conditional independence and dependence
models. However, those dependence models are not directly applicable in the setting that we
are considering because there are only two diagnostic tests, and more importantly, if both
diagnostic tests are negative, no further gold standard classification will be applied.
Let T1, T2, and D be the random variables denoting the two screening tests and the disease
status, respectively. In this article, we consider T1 and T2 to be binary variables with value 1
indicating test positive and 0 indicating test negative, and D to be a categorical variable with
value d = 1, 2,…, K indicating the classes of disease. Let  be the observed frequency with
D= d, T1 = i and T2 = j (i = 0, 1 and j = 0, 1),  be the observed frequency with T1 =
i and T2 = j, and  be the total number of observations. Furthermore, let πij = P(T1
= i, T2 = j), , Pd = P(D = d),
, and
 denote the corresponding joint, marginal and conditional
probabilities. In most studies, we only observe frequencies of  and  due to the
nature of screening. The frequencies of  are usually not observed, although the margin
 is observed. The data structure contains 3d+1 observed frequencies, which in
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general allows for the estimation of a maximum of 3d free parameters. In this paper we will
not consider special cases when only less than 3d free parameters are identifiable, e.g., when
there are zeros among the observed frequencies.
One way to write the likelihood function (ignoring constant terms) in this setting is in terms
of Pd and  (d = 1, 2,…, K; i = 0, 1; j = 0, 1) with constraints of  and 
as follows,
(1)
This parameterization involves a mixture likelihood in the first term and prevents a closed-
form solution for the maximum likelihood estimators (MLE). It contains 4d−1 free
parameters. Without further assumptions, the parameters in equation (1) are not identifiable.
However, this parameterization allows for direct specification of commonly used
assumptions, usually specified through some constrains on . For example, the frequently
used conditional independence assumption [15,16] assumes that the two tests T1 and T2 are
independent conditioning on the disease status D, i.e., T1⊥T2|D, and the number of free
parameters in equation (1) is reduced to 3d−1 giving model identification since
, and . For
convenience, we denote the conditional independence model as the ⊥ model with  as the
corresponding MLEs. Under the homogeneous dependence assumptions (i.e., the α, θ, and ρ
models that will be discussed in Sections 2 and 3), the number of free parameters in equation
(1) is reduced to 3d and the models become saturated and equivalent to the alternative
parameterization below [17].
An alternative parameterization of the log-likelihood function can be written in terms of πij
(i = 0, 1; j = 0, 1) and  with constraint of  as
follows,
(2)
This representation relates to previous work in other settings [18–20]. This model is a
saturated model with 3d parameters. The maximum likelihood equations are tractable and
yield MLEs in closed-form. Omitting the algebra, we obtain, π̂ij = xij/n (i, j =0, 1), and
 if i + j>0. The existence of closed-form solutions for this alternative
parameterization allows for closed- form solutions for the α and θ homogeneous conditional
dependent models [17], which will be briefly discussed in detail in Sections 2.1 and 2.2.
Furthermore, this saturated alternative parameterization also suggests that the probability of
having disease class d for those with both tests negative (i.e., ), and further the overall
probability of having disease class d (i.e. ) are not identifiable without some
additional “non-testable” assumptions. Thus, the dependence structure modeling considered
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in this paper itself is not “testable”, and can only be viewed as a sensitivity analysis for the
estimation of disease prevalence. Similar to generalized linear models with non-ignorable
missing data mechanism [21], the type of sensitivity analyses play an important role in the
estimation and inference in this problem.
In similar settings when the gold standard was only measured on those who screened
positive, Cheng et al. [22] and Pepe and Alonzo [23] have examined the potential
overwhelming impact of the correlation between the two screening tests on the estimation of
absolute test accuracy parameters. Both suggest using relative test accuracy for comparing
disease screening tests. However, to our knowledge, no one has assessed the impact of the
misspecification of conditional dependence structures, which can be specified by a
homogeneous dependence parameter for two diagnostic tests, on the estimation of disease
class probabilities in such screen-positive ascertained studies.
In this article, we empirically assess the impact of misspecification of the conditional
dependence structure on the estimation of disease class probabilities through two case
studies and simulations. Specifically, in Sections 2.1 and 2.2, we define the MLEs for the
homogeneous dependent α and θ models, and in Section 2.3 we propose the homogeneous
correlation coefficient conditional dependent ρ model. Bayesian approaches, which
incorporate prior beliefs about dependence, are developed for the three models in Section 3
as an alternative to the maximum likelihood methods. Furthermore, we discuss Bayesian
model averaging in Section 3.4 as an alternative way to address the challenging estimation
problem since the three homogeneous dependent models can provide the same goodness-of-
fit for the data but substantively different estimates [17] and the dependence structure itself
is not “testable”. In Section 4, we compare the results for the two case studies using both the
maximum likelihood methods and the Bayesian approaches. The two case studies were
reanalyzed recently by Böhning and Patilea [1] using a capture-recapture approach under the
α and θ model assumptions. Our focus here is to compare the estimates under the α, θ and ρ
model assumptions using both the maximum likelihood methods and Bayesian approaches.
A simulation study is conducted in Section 5 and a brief discussion is presented in Section 6.
2. Maximum Likelihood Estimators for Models with Homogeneous
Dependence
In Section 2.1 and 2.2, we will briefly introduce the homogeneous conditional dependence α
and θ models, recently proposed by Böhning and Patilea [1] using a capture-recapture
approach. Using the alternative parameterization of the maximum likelihood as presented in
equation (2), Chu and Nie [17] presented closed-form maximum likelihood solutions under
the α and θ model assumptions.
2.1 Homogeneous conditional dependence: the α model
Under this model, the association of the two tests T1 and T2 conditional on the disease status
D as measured by the odds ratio is assumed to be homogeneous over all disease categories,
i.e.,  (d = 1, 2, …, K) is assumed to be homogenous. By Bayes’ theorem, we
obtain . With  and simple algebra, we obtain the solution of
 under this homogeneity assumption. Thus, by plugging in the
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closed-form solutions of MLEs of π (i, j =0, 1) and  from equation (2), the closed-
form MLEs of α and  are
(3)
where the superscript α indicates the homogeneous odds ratio assumption.
2.2 Homogeneous conditional dependence: the θ model
Under this model, ratio of conditional (conditional on test T2 being positive) and
unconditional probabilities of test T1 being positive is assumed to be homogeneous over all
disease categories, i.e.,  (d = 1, 2, …, K) is assumed to be homogenous. By Bayes’
theorem, we obtain . With  and simple
algebra, we obtain the solution of . Thus,
the closed- form MLEs of θ and  are
(4)
where the superscript θ indicates the homogeneous relative risk assumption.
2.3 Homogeneous conditional dependence: the ρ model
In this section, we propose an alternative homogeneous conditional dependence model, the ρ
model. Under this model, the correlation of the two tests T1 and T2 is assumed to be
homogeneous over all disease categories, i.e., ρd(d = 1, 2, …, K) is assumed to be
homogenous ρ. Let  be the covariance between two tests
in the dth disease group, then we have
, and
. The bounded range of correlations is determined by the
marginal probability of testing positive  and . Specifically, the correlation coefficients
ρ satisfies
(5)
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Let the MLEs of ρ and Pd be denoted as ρ̂ and , where the superscript ρ indicates the
homogeneous correlation coefficient assumption. They do not have a closed-form solution
under this model.
All three models assume a homogeneous dependence structure. This is a rather strong
assumption. However, because all three homogeneous dependent models are already
saturated, heterogeneous dependent models are not identifiable without additional
constraints on test accuracy parameters (e.g., assuming the test accuracy parameters are the
same for the two diagnostic tests, which is a much stronger assumption in general).
Furthermore, the three homogeneous dependent models can provide the same goodness-of-
fit for the data but substantively different estimates [17], a natural way addressing this
problem might be through the frequentist model average estimators [24]. Let wα, wθ and wρ
with constraint of wα + wθ + wρ= 1 be the corresponding weights for the α, the θ, and the ρ
models, the weighted model average estimator can be defined as .
However, the MLEs  and  are usually correlated since they are based on the same
data. Due to the technical difficulty of computing the variance-covariance matrix between
( ) and  for the computation of the standard error of , we do not consider the
frequentist model average estimator in this article. We will consider the Bayesian model
averaging counterpart in Section 3.4.
In practice, it is often of interest to test the difference between the estimated probabilities of
disease states using different dependence assumptions (i.e., the α, θ or ρ model). Since the
closed-form maximum likelihood solutions for the α and θ models are based on the
likelihood function as presented in equation (2), a Wald-type test comparing  is
directly available with the standard error  obtained by the delta method. Due to
the technical difficulty of computing the variance-covariance matrix between ( ) and
, comparing the MLEs of ( ) with  is not straightforward. In practice,
bootstrapping methods can be used as an alternative way to compute the corresponding p-
values and 95% confidence intervals [25].
We developed a SAS macro (SAS Institute, Cary, NC) to implement the models discussed
above parameterized both in terms of Pd and  as in equation (1) for the homogeneous ρ
model, and in terms of πij and  as in equation (2) for the homogenous α and θ models. To
describe disease class prevalence and to implement the constraints of 0 < Pd < 1 and
, we used the linear generalized logit model [26] which is widely applied in
categorical data analysis. This model has an inverse link function defined as 
(d = 1, 2, …, K) with βK = 0. We used the delta method to compute the standard error of
functions of MLEs and their confidence intervals based on normal approximation. The two
parameterizations (i.e., in terms of Pd,  and in terms of πij, ) provide exactly the same
results.
3. Bayesian Estimation for Models with Homogeneous Dependence
In this Section, we discuss the Bayesian approaches [27,28]. Because the Bayesian approach
and the frequentist approach use different frameworks, they can be considered
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complementary. When relatively large studies are combined with weak prior distributions,
inferences obtained by Bayesian and frequentist methods generally agree. However, the
Bayesian framework is particularly attractive when suitable prior distributions can be
constructed to incorporate known constraints and subject-matter knowledge on model
parameters [29]. The Bayesian framework allows direct construction of 100(1−α)% equal
tail and highest probability density (HPD) credible intervals of general functions of the
estimated parameters without having to rely on asymptotic approximations. Furthermore, the
Bayesian framework provides direct implementation of model averaging [30], which
provides a natural way to address the problem of selecting a model from several competing
models that give equal goodness-of-fit but potentially different inferences for a particular
study.
3.1 Homogeneous conditional dependence: the α model
To implement the constrains of  and  under the α model, we re-
parameterize  and  as follows,
(6)
Let f(α, ad, bd, Pd) be the prior joint distribution of (α, ad, bd, Pd) (d = 1, 2, …, K), the joint
posterior distribution given the observed frequencies is proportional to
(7)
3.2 Homogeneous conditional dependence: the θ model
To implement the constrains of  and  under the θ model, we re-
parameterize  and  as follows,
Let  be the prior joint distribution of (θ, , Pd) (d = 1, 2, …, K), the
joint posterior distribution given the observed frequencies is proportional to
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The feasible range of θ is determined by the marginal probability of testing positive  and
 and is implemented through the addition of the four indicator functions I(·) in equation
(8).
3.3 Homogeneous conditional dependence: the ρ model
To implement the constrains of  and ρd=ρ (d = 1, 2, …, K), we re-parameterize
 and  as in equation (6). Let f(ρ, ,Pd) be the prior joint distribution of
(θ, ,Pd) (d = 1, 2, …, K) and  be the covariance,
the joint posterior distribution given the observed frequencies is proportion to
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The feasible range of correlation determined by the marginal probability of test positive 
and  as in equation (5) is implemented through the addition of the four indicator
functions I(·) in equation (9).
3.4 Homogeneous conditional dependence: Bayesian model averaging (BMA)
The homogeneous dependence models are saturated. Therefore, they provide the same
goodness-of-fit for the data, but can provide substantively different estimates. Bayesian
model averaging (BMA) provides a natural way to address this problem [30]. The posterior
distribution of the quantity of interest Pd given data is
(10)
where M1 …, MK are the models considered, and the posterior probability for model Mk is
given by , where pr(Data|Mk)= ∫ pr(Data|ϑk,
Mk)pr(ϑk|Mk)dϑk is the integrated likelihood of model Mk, and ϑk is the vector of
parameters of model Mk, pr(ϑk|Mk) is the prior density of ϑk under model Mk, pr(Data|ϑk,
Mk) is the likelihood, and pr(Mk) is the prior probability that Mk is the true model (assuming
one of the models considered is true). In this paper, we assume equal prior probabilities for
the α, θ and ρ models, i.e., pr(Mk)=1/3 for k=1,2,3.
In the Bayesian models discussed above, computation was done using Markov chain Monte
Carlo (MCMC) [31] in WinBUGS [32] and BRUGs in R (http://www.r-project.org). Burn-in
consisted of 50,000 iterations; 50,000 subsequent iterations were used for posterior
summaries. Convergence of Markov chains was assessed using the Gelman and Rubin
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convergence statistic [33,34]. To describe disease class prevalence and to implement the
constrain of 0 < P < 1 and , we use the linear generalized logit model which has
inverse link function defined as  (d = 1, 2, …, K) with βK = 0 [26]. We
selected proper but diffuse prior distributions for the hyperparameters [35]. Specifically, the
hyper-priors for the parameters were assumed to be as follows: 1) Vague priors of N(0, 103)
were assumed for βd s (d = 1, 2, …, K−1) in the generalized logit transformed probabilities
of disease classes Pd s; 2) Uniform prior of [−1.0, 1.0] was assumed for correlation
coefficient ρ; 3) Vague priors of N(0, 103) were assumed for α and θ on the log scale to
ensure α > 0 and θ > 0; and 4) Vague priors of N(0, 103) were assumed for ad s and bd s in
the α model to directly implement the homogeneous odds ratios assumption, and for s
and s in the logit scale for the θ and ρ models.
4. Two Case Studies
For the purpose of comparing the performance of different models, we reanalyzed the data
from two screening studies, in which the disease status has been evaluated only for those
who tested positive for at least one of the two tests. The first study consists of data from the
Health Insurance Plan Study for screening breast cancer in New York [36]. The study was
carried out by the Health Insurance Plan, a prepaid comprehensive medical care plan with
750,000 subscribers enrolled in 31 medical groups. Periodic screening for breast cancer
using mammography as well as clinical physical examination was performed for women
aged 40 to 64 years who were chosen at random. In this study, 307 out of 20,211 women,
who were test positive by either physical examination or mammography, underwent biopsy
for the classification of two disease states: no cancer (d = 1) or cancer (d = 2). The second
study is the multicenter study comparing cervicography with the standard pap smear
cytology test for detecting cervical cancer between November 1991 and December 1992
[37]. In this study, 228 out of 5,192 women, who were test positive by either cervicography
or the standard pap smear cytology test, underwent biopsy for the classification of three
disease states: not present (d = 1), low grade (condyloma) (d = 2) and high grade (invasive
cancer) (d = 3). Table 1 presents the observed frequencies in the two screening studies.
Table 2 presents the estimates of the conditional dependence parameters (i.e., α, θ and ρ)
when using both the maximum likelihood method and the Bayesian method. We use the
triple of percentiles, 2.55097.5, to display a parameter estimate (or posterior median) with its
95% confidence (or credible) interval, as suggested by Louis and Zeger [38]. In summary,
both approaches suggest statistically significant dependence when using all three models for
the two studies. Tables 3 and 4 present the estimated probabilities of the disease classes
under the three homogenous dependence models as well as under the independence model,
when using the maximum likelihood method and the Bayesian method, respectively. The
twice negative likelihood is presented in Table 3 for comparing the goodness-of-fit of the
independent ⊥ model, and the homogeneous dependent α, θ, and ρ models, which
demonstrate that the α, θ, and ρ models give exactly the same goodness-of-fit for both
studies. In addition, the BMA estimates across the three conditional dependence models are
presented in Table 4. In summary, the estimates were consistent between the maximum
likelihood and Bayesian approaches except for the probabilities of not present and low grade
cervical cancer in the multicenter study detecting cervical cancer using the ρ model,
potentially due to the constrains implemented in the Markov chain Monte Carlo samplings.
Specifically, the estimated probability of low grade cervical cancer is estimated to
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be 54255883 per 1000 women using the Bayesian approach, but only 0115308 per 1000
women using the maximum likelihood method.
As an interesting observation, we found that the difference between the estimated
probabilities of disease states using different dependence assumptions (i.e., the α, θ or ρ
model) can be statistically significant and practically meaningful. For example, in the Health
Insurance Plan Study for breast cancer screening in New York, the estimated probability of
having breast cancer using the maximum likelihood method is 34893 per one thousand
women assuming the α model, while the estimate is 2875122 per one thousand women
assuming the θ model, and 2711 per one thousand women assuming the ρ model. The
difference between the estimated probabilities of having breast cancer assuming α and θ
models is 142740 per one thousand women with a p-value less than 0.001 by a Wald-type
test. The non-overlapping 95% confidence intervals between the estimated probabilities
assuming the ρ model and the α (or θ) model suggests a statistically significant difference at
least at the 5% significant level. In addition, using the maximum likelihood approach, the
estimated probability of having invasive high grade cervical cancer is 286194 per one
thousand in the multicenter study for detecting cervical cancer assuming the θ model, which
is about eight times higher than the estimate of 5811 per one thousand women assuming the ρ
model, and the 95% confidence intervals do not overlap. The Bayesian approaches gave
similar inferences to the frequentist approaches. This substantial difference in estimated
probability high grade cervical cancer can have an impact on cancer surveillance and
prevention. Unfortunately, the data does not contain any information to differentiate those
dependent models since they all give the same goodness-of-fit. Thus, without some sensible
assumptions, the disease prevalence may not be estimable from the data set, even with
Bayesian model averaging, particularly if proposed models in BMA do not contain the
correct model (which is arguably true in practice given that an infinite large number of
models exist and potentially many can give same goodness of fit).
5. Simulation Studies
To further study how the disease status probability estimates vary with the dependent model
assumption and to evaluate the impact of misspecification of different dependent models on
the estimation of the probabilities of disease classes, we performed four sets of simulations
assuming the independent model, the α, θ, and ρ dependent models, respectively. For ease of
presentation and interpretation, we considered two disease strata. The simulation parameters
are: the probabilities of disease classes Pd = (0.8,0.2), the marginal conditional probabilities
of test T1 being positive , and the marginal conditional probabilities of test
T2 being positive . In the α and θ models, we used two values of α (or θ) =
1.25 and 3.0. In the ρ model, we used two values of ρ = 0.2 and 0.6. The sample sizes
considered were n = 5000 and 25000. For each combination of α (or θ, or ρ) and n values,
we generated 2,000 replicates. For each replicate, we computed the estimators under the
independent model, the dependent α, θ, and ρ models, using both the maximum likelihood
and Bayesian approaches. In addition, the BMA estimators across the three dependent
models were computed. We used the true values of Pd,  and , α = 1, θ =1, and ρ = 0 as
the starting values in the maximum likelihood optimization procedures and the Bayesian
Markov chain Monte Carlo sampling procedures.
Table 5 presents the means of the estimated disease prevalence across 2,000 replicates, using
both the maximum likelihood and Bayesian approaches. For the Bayesian models, posterior
medians were used as estimates for disease prevalence for a single replicate. If the true
underlying model is the conditional independence model, fitting the α, θ and ρ dependence
models will provide unbiased estimates for the disease prevalence. However, if the
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underlying model is one of the three dependence models, assuming independence provides
biased estimates for disease prevalence. In addition, if the underlying model is a dependence
model, assuming an incorrect dependence structure leads to biased estimates for disease
prevalence. One interesting observation is that Bayesian model averaging (BMA) estimates
tend to be less biased than the estimates under a misspecified dependence model.
Furthermore when the underlying model is the α dependent model, the BMA estimates lead
to nearly unbiased estimates. For all the scenarios, the maximum likelihood and Bayesian
approaches provide similar estimates.
Table 6 presents the average length of the 95% confidence/credible intervals or the precision
of the disease prevalence estimates across 2,000 replicates when using the maximum
likelihood and Bayesian approaches. We found that if the true underlying model is the
conditional independence model, assuming the α and θ dependence models leads to intervals
that are too wide. For example, the 95% confidence/credible interval length using the θ
dependence model is about twice than that using the true independence model. This suggests
a substantive efficiency loss when conservatively assuming the α and θ dependence models.
However, if the ρ dependence model is assumed, the average interval lengths are only
slightly inflated. On the other hand, if the underlying model structure is one of the three
dependence models, assuming independence leads to intervals that are too narrow (and
biased). In addition, if the underlying model is the θ model, incorrectly assuming the α and ρ
dependence models also leads to underestimation of the interval length. Furthermore, the
results are highly concordant between the maximum likelihood and Bayesian approaches.
Note that the average interval lengths of the BMA estimates are generally larger than those
under any dependence model alone, regardless of whether the dependence model is correctly
or incorrectly specified. This is due to the fact that the BMA estimates incorporate the
additional uncertainty from model specification.
Table 7 presents the coverage performance of the 95% confidence/credible intervals of the
disease prevalence across 2,000 replicates using both the maximum likelihood and Bayesian
approaches. The coverage upon misspecification using dependent models is still around 95%
if the true underlying model is the conditional independence model, possibly due to the
negligible bias and wider confidence/credible intervals upon such misspecification, as
suggested in Tables 5 and 6. However, if the underlying model structure is one of the three
dependent models, the coverage upon misspecification decreases as the degree of
dependence increases and as the sample size increases. In addition, the results suggest that if
the underlying model is the ρ model, decent coverage tends to be difficult when the model is
misspecified. In general, the Bayesian 95% credible intervals show slightly better coverage
compared with the maximum likelihood 95% confidence intervals. More importantly, the
coverage of the BMA intervals generally exceeds 90%, which has much better performance
than the intervals from any single misspecified model. One reason for the better coverage
using BMA is that such intervals are generally wider than those under a single model alone,
and the true underlying model is included in the model averaging.
6. Discussion
For screening studies where a categorical disease status is verified only if at least one out of
the two binary screening tests being positive, we investigated three homogeneous
dependence models (i.e., the α, θ, and ρ models) with two case studies and four sets of
simulation studies, in which the ρ model is proposed in this paper. If the true underlying
model is the conditional independence ⊥ model, assuming the α and θ dependence models
leads to intervals that are too wide (i.e., the 95% confidence/credible interval length of the θ
model can be as twice as that of the ⊥ model), while the ρ dependence model only slightly
inflated the average interval lengths. By two real data analyses and simulation studies, we
Chu et al. Page 12













demonstrated that the three homogeneous dependence models can provide substantively
different estimates for a study although with the same goodness-of-fit. We discussed both
the frequentist and Bayesian approaches, and evaluated the impact of model
misspecification on the estimation of disease class probabilities. Furthermore, we discussed
Bayesian model averaging as an alternative way to partially address this particularly
challenging estimation problem. Although we focused on the inference of disease class
probabilities in this article, the same conclusion applies to the inference of the cell
probabilities for two negative tests, i.e., , and the unknown cell frequency . We did not
discuss the impact of misspecification of dependence structures on the estimation of test
accuracies because it has been well studied from frequentist perspective [5,10,39]. It might
be of interest to compare the performance of frequentist and Bayesian approaches on the
estimation of test accuracy parameters under different settings such as low, moderate and
high sensitivities and specificities.
The results imply that large differences in the estimated disease class probabilities may
occur when assuming different dependence models, which can have a substantial impact on
disease surveillance and prevention. Other more robust statistical methods, e.g. the
generalized estimation equations [40,41], may be used to reduce the impact from
misspecification of the dependence structure in this setting. We do not intend to suggest that
these homogeneous dependence models are useless in practice because we cannot
statistically differentiate between them based on the data alone. Caution against using these
models due to the possible misspecification should be balanced with the need to estimate
disease status probabilities. Furthermore, we realize that there are many more potential
dependence structures than what we have considered, e.g., one could argue that the tests are
dependent only for the cases but are independent for the controls [42]. Depending on the
problem in hand, some assumptions may be justifiable and preferable. In addition, note that
the indistinguishable characteristic of these models is based on goodness-of-fit statistics
alone. We can always use additional information such as expert opinion, historic
information on sensitivities and specificities of the two binary diagnostic tests, and/or the
range of dependence parameters to assist our choice of selecting a homogeneous dependence
model. For the Bayesian approach, the additional information can be formulated as
informative priors to improve the posterior inference. However, how to solicit and formulate
informative priors in this case deserves thorough investigation and is beyond our current
scope.
A potential strategy to justify the homogeneous assumptions of the α, θ and ρ is to
incorporate a design element into the screening study that allows the selection of
homogeneity models. This strategy could be randomly selecting a subset of both test
negatives for ascertainment by a gold standard. However, in cases when a gold standard test
is invasive and/or expensive, it is generally considered unethical to apply it to subjects
whose screening tests are negative. In this case, if historical data or additional sample from a
set of confirmed cases and controls in a similar population is available for determining test
accuracy parameters, one can use the data to guide the selection of homogeneity dependence
models.
In cases when there is no scientific justification to prefer a particular dependence model over
the others, we suggest to treat those dependence models (including the three homogeneous
dependence models that we have considered) as sensitivity analyses, and investigate how the
dependence structure will impact the estimation of probabilities of disease classes. If there is
a clinically significant difference, caution should be taken with any statistical inference. As a
last choice, if the dependence structure assumption cannot be reasonably determined,
Bayesian model averaging (BMA) may be preferable to any single model, but there is a
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heavy price to pay for the BMA: 1) the computations become more complex and 2) the
credible intervals get much larger in some cases (to reflect the added uncertainty).
Assuming that models used in the Bayesian averaging includes the correctly specified
model, the simulation results show that BMA inference generally performs better than any
misspecified model alone, especially with respect to the interval coverage performance. In
practice, all candidate models can be misspecified and thus one can argue that Bayesian
model averaging may not be effective in reducing bias. Intuitively, if some models tend to
overestimate and the other models tend to underestimate the parameters of interest, then the
Bayesian model averaging will be effective in reducing bias compared to a specific
misspecified model. However, we realize that if all models tend to overestimate (or
underestimate) the parameters of interest or if the estimates from the incorrect models are far
away from the correct model estimates, then the Bayesian model averaging may not be
effective in reducing bias. In addition, because the data do not contain information to
distinguish between conditional dependence models, one should not expect that the posterior
model probabilities to be accurately estimated in practice, casting some doubt on the utility
of the BMA estimate in this case.
In this article we consider only homogeneous dependence models which are identifiable
from are data setting. Some researchers [43,44] have argued that one can do better in using a
non-identifiable model with some informative prior information compared to a less realistic
model with strong assumptions that is identifiable. Further research on an expanded model,
potentially with heterogeneous dependence structure, may shed more light on the impact of
prior misspecification versus model misspecification and the trade-off between an expanded
non-identifiable model with less model assumption but more prior assumption and an
identifiable model with stronger model assumption but less prior assumption on the
estimation of disease prevalence in the case that we discussed.
We assumed that a perfect gold standard (or definitive) test exists, which may limit the
usage of the proposed methods, because arguably all diagnostic tests are imperfect and even
those with theoretically perfect properties can be rendered imperfect by laboratory or human
errors. It may be fruitful for further methodological research to incorporate measurement
errors of the third stage gold standard test, e.g., by a sensitivity analysis [45] or multiple
imputation [46]. However, this is beyond our present scope.
Another important potential bias in the estimation of disease prevalence is selection bias as
to who participates in the screening program. We acknowledge that the estimates from our
method can be biased if those who participate in the screening program are not
representative of the target population whose prevalence is being estimated. If the
information on who tend to participate in the screening program is available, further
adjustment for the selection bias can be done by e.g., multiple imputation or inverse
probability weighting (i.e., weighting each participant by the inverse of its estimated
probability of participating the screening program).
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